GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Beneish M-Score

Australian Clinical Labs (ASX:ACL) Beneish M-Score : -3.45 (As of Mar. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Australian Clinical Labs's Beneish M-Score or its related term are showing as below:

ASX:ACL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.66   Med: -3.45   Max: -2.69
Current: -3.45

During the past 5 years, the highest Beneish M-Score of Australian Clinical Labs was -2.69. The lowest was -3.66. And the median was -3.45.


Australian Clinical Labs Beneish M-Score Historical Data

The historical data trend for Australian Clinical Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Beneish M-Score Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24
Beneish M-Score
- - -2.69 -3.66 -3.45

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Beneish M-Score Get a 7-Day Free Trial - -3.66 - -3.45 -

Competitive Comparison of Australian Clinical Labs's Beneish M-Score

For the Diagnostics & Research subindustry, Australian Clinical Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australian Clinical Labs's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Beneish M-Score falls into.



Australian Clinical Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Australian Clinical Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1086+0.528 * 0.9889+0.404 * 0.9943+0.892 * 0.9966+0.115 * 0.9534
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.055+4.679 * -0.223672-0.327 * 0.9973
=-3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Total Receivables was A$81.4 Mil.
Revenue was A$689.7 Mil.
Gross Profit was A$570.4 Mil.
Total Current Assets was A$133.6 Mil.
Total Assets was A$593.1 Mil.
Property, Plant and Equipment(Net PPE) was A$281.7 Mil.
Depreciation, Depletion and Amortization(DDA) was A$128.4 Mil.
Selling, General, & Admin. Expense(SGA) was A$312.7 Mil.
Total Current Liabilities was A$207.7 Mil.
Long-Term Debt & Capital Lease Obligation was A$204.2 Mil.
Net Income was A$23.9 Mil.
Gross Profit was A$-3.0 Mil.
Cash Flow from Operations was A$159.6 Mil.
Total Receivables was A$73.7 Mil.
Revenue was A$692.1 Mil.
Gross Profit was A$566.0 Mil.
Total Current Assets was A$116.0 Mil.
Total Assets was A$578.9 Mil.
Property, Plant and Equipment(Net PPE) was A$288.4 Mil.
Depreciation, Depletion and Amortization(DDA) was A$122.8 Mil.
Selling, General, & Admin. Expense(SGA) was A$297.4 Mil.
Total Current Liabilities was A$187.9 Mil.
Long-Term Debt & Capital Lease Obligation was A$215.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(81.434 / 689.728) / (73.71 / 692.103)
=0.118067 / 0.106501
=1.1086

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(566.02 / 692.103) / (570.408 / 689.728)
=0.817826 / 0.827004
=0.9889

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (133.601 + 281.704) / 593.06) / (1 - (115.959 + 288.438) / 578.913)
=0.299725 / 0.301455
=0.9943

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=689.728 / 692.103
=0.9966

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(122.755 / (122.755 + 288.438)) / (128.427 / (128.427 + 281.704))
=0.298534 / 0.313137
=0.9534

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(312.668 / 689.728) / (297.394 / 692.103)
=0.453321 / 0.429696
=1.055

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((204.19 + 207.703) / 593.06) / ((215.234 + 187.925) / 578.913)
=0.694522 / 0.696407
=0.9973

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(23.934 - -3.007 - 159.592) / 593.06
=-0.223672

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Australian Clinical Labs has a M-score of -3.45 suggests that the company is unlikely to be a manipulator.


Australian Clinical Labs Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines